the Safety and Efficacy of SENL103 Autologous T Cell Injection

Clinical trial NCT06067581 · UNKNOWN

Trial details

NCT number: NCT06067581
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2023-08-21
Primary completion: 2025-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.